Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) Equity Average (2022 - 2025)

Historic Equity Average for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $323.2 million.

  • Centessa Pharmaceuticals' Equity Average fell 1775.97% to $323.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $323.2 million, marking a year-over-year decrease of 1775.97%. This contributed to the annual value of $318.9 million for FY2024, which is 1142.11% up from last year.
  • Per Centessa Pharmaceuticals' latest filing, its Equity Average stood at $323.2 million for Q3 2025, which was down 1775.97% from $365.6 million recorded in Q2 2025.
  • Centessa Pharmaceuticals' Equity Average's 5-year high stood at $450.3 million during Q4 2024, with a 5-year trough of $225.7 million in Q1 2024.
  • For the 4-year period, Centessa Pharmaceuticals' Equity Average averaged around $337.1 million, with its median value being $338.9 million (2022).
  • Its Equity Average has fluctuated over the past 5 years, first tumbled by 3669.48% in 2023, then skyrocketed by 8172.32% in 2024.
  • Quarter analysis of 4 years shows Centessa Pharmaceuticals' Equity Average stood at $354.5 million in 2022, then crashed by 30.1% to $247.8 million in 2023, then skyrocketed by 81.72% to $450.3 million in 2024, then decreased by 28.22% to $323.2 million in 2025.
  • Its last three reported values are $323.2 million in Q3 2025, $365.6 million for Q2 2025, and $393.9 million during Q1 2025.